LifeStance Health Group (NASDAQ: LFST) insider transactions
In the twelve months to 10 November 2026, executives and directors of LifeStance Health Group reported 37 open-market sales of 94,086,889 shares ($847.2m) and 0 open-market purchases, by 9 people, according to the Form 4 filings they submitted to the SEC.
Latest transactions
| Date | Insider | Role | Transaction | Shares | Price | Held after | Filing |
|---|---|---|---|---|---|---|---|
| 22 September 2026 | Bourdon David | Chief Executive Officer | Gift | −150,000 | — | 1,098,247 | Form 4 |
| 22 September 2026 | Bourdon David | Chief Executive Officer | Gift | +150,000 | — | 150,000 | Form 4 |
| 22 September 2026 | Bourdon David | Chief Executive Officer | Gift | −150,000 | — | 948,247 | Form 4 |
| 22 September 2026 | Bourdon David | Chief Executive Officer | Gift | +150,000 | — | 150,000 | Form 4 |
| 11 September 2026 | Tpg GP A, Llc | — | Open-market sale | −18,409,705 | $12.29 | 79,691,702 | Form 4 |
| 2 September 2026 | Paunovich Vukasin | Chief Technology Officer | Open-market sale | −42,067 | $12.87 | 205,379 | Form 4 |
| 2 September 2026 | Bourdon David | Chief Executive Officer | Other | −150,000 | — | 1,248,247 | Form 4 |
| 24 August 2026 | Varanakis Ann | Chief People Officer | Shares withheld for tax | −8,156 | $12.16 | 413,881 | Form 4 |
| 14 August 2026 | DeLuca Teresa | Director | Open-market sale | −7,500 | $12.68 | 97,093 | Form 4 |
| 13 August 2026 | DeLuca Teresa | Director | Open-market sale | −20,441 | $12.23 | 104,593 | Form 4 |
| 11 August 2026 | Burdick Kenneth A | Director | Open-market sale | −500,000 | $11.51 | 2,970,810 | Form 4 |
| 10 August 2026 | Miller Lisa K | Chief Operating Officer | Open-market sale | −47,912 | $10.85 | 281,289 | Form 4 |
| 10 August 2026 | Paunovich Vukasin | Chief Technology Officer | Open-market sale | −44,394 | $10.85 | 247,446 | Form 4 |
| 10 August 2026 | Tpg GP A, Llc | — | Open-market sale | −13,643,207 | $10.62 | 98,101,407 | Form 4 |
| 6 July 2026 | Burdick Kenneth A | Director | Grant or award | +45,495 | — | 3,470,810 | Form 4 |
| 2 July 2026 | Goltermann Lori | Director | Grant or award | +35,492 | — | 35,492 | Form 4 |
| 2 July 2026 | Justice Thurman | Director | Grant or award | +35,492 | — | 35,492 | Form 4 |
| 2 July 2026 | DeLuca Teresa | Director | Grant or award | +17,746 | — | 125,034 | Form 4 |
| 2 July 2026 | Personette Sarah | Director | Grant or award | +17,746 | — | 92,512 | Form 4 |
| 2 July 2026 | Bessler Robert | Director | Grant or award | +17,746 | — | 75,365 | Form 4 |
Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.
How to read the table
Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.
Where each row comes from
From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the LifeStance Health Group page; the method, in data sources.
Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.